RESUMO
Hydroxychloroquine (HCQ) is an antimalarial that is utilized to treat a range of dermatologic and autoimmune disorders. With its ability to alter immunologic mechanisms, it has been used to slow or halt the progression of hair loss in conditions secondary to autoimmune dysfunction. Lichen planopilaris (LPP), frontal fibrosing alopecia (FFA), and alopecia areata (AA) are hair disorders with underlying autoimmune components and no standardized treatment guidelines. We summarized the available literature on the use of HCQ to treat LPP, FFA, and AA. For all three conditions, HCQ showed variable efficacy from halted hair loss to no improvement. While patients did show success with HCQ treatment, there were no clear treatment patterns. Regimens ranged from HCQ monotherapy to combination treatments with other agents like steroids. Overall, HCQ should certainly be considered by clinicians as a treatment option for patient suffering from these hair disorders. While there is no standardized treatment, incorporation of HCQ should take into consideration individual patient characteristics, clinical judgment, and risks of side effects.
Hydroxychloroquine (HCQ) is an antimalarial drug that acts on the immune system. Lichen planopilaris, frontal fibrosing alopecia, and alopecia areata are all disorders that result in hair loss secondary to immune dysfunction. HCQ has been used to treat these conditions, so publications addressing HCQ use for such hair loss disorders were collected, and the findings were summarized. Overall, HCQ showed mixed efficacy but can be a successful treatment option for some patients. Various treatment patterns were seen from using only HCQ to combination therapy plans with HCQ and steroids, for example. Treating these hair loss conditions can be challenging, and while there are no standardized guidelines, HCQ should be considered in the treatment arsenal for patients.
RESUMO
BACKGROUND: Pemphigoid nodularis is a rare clinical variant of bullous pemphigoid characterized by overlapping clinical features of both prurigo nodularis lesions and bullous pemphigoid blisters. The condition appears to be more common in females and is often resistant to treatment. OBJECTIVE: To raise awareness of this rare variant of bullous pemphigoid. METHODS: Case report. RESULTS AND CONCLUSION: Dermatologists should include this variant in differential diagnosis of prurigo nodularis because early recognition can lead to an effective treatment for the prurigo component.